Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • CDSCO pulls...

    CDSCO pulls manufacturers for failing to submit application for category d FDCs; Details

    Farhat NasimWritten by Farhat Nasim Published On 2020-02-14T12:31:32+05:30  |  Updated On 14 Feb 2020 12:31 PM IST
    CDSCO pulls manufacturers for failing to submit application for category d FDCs; Details

    New Delhi: Through a recent notification, the Central Drugs Standard Control Organization (CDSCO) has pulled up the Fixed-Dose Combination (FDCs) manufacturers and directed them to submit an application for category 'd' Fixed-Dose Combinations (FDCs) as per Kokate Committee Report by May 30, 2020.

    The Kokate Committee, headed by Prof. C. K. Kokate, Former Vice-Chancellor, KLE University, Karnataka, examined the Safety and Efficacy of unapproved FDCs which were licensed by State Licensing Authorities without due approval of DCGI.

    The Committee had examined 418 applications of FDCs and found 324 FDCs as irrational while only 28 FDCs as rational. The panel had further stated that they require more data for 2 FDCs and 4 FDCs require further deliberation. It was also observed that out of the remaining 60 FDCs, 48 FDCs have already been prohibited, 11 have been declared rational and one FDC is sub judice.

    Also Read: CDSCO Expert Committee Suggests Ban Of Yet Another 324 FDCs

    The last date for filing such application was decided as November 22, 2019. However, with the expiry of the last date, CDSCO has provided another chance to the FDC manufacturers by giving them more time for submission of the application. In this regard, the apex drug regulator has extended the last date till May 30, 2020.

    The extension came following various representations received by the Drugs Controller General of India (DCGI), requesting for an extension of time for submission of such applications. Accordingly, it has been decided that manufacturers or stakeholders who were holding license prior to October 1, 2012, may submit their applications with respect to category 'd' FDCs by May 30, 2020.

    A letter on the same has also been sent to all the state drugs controllers and India drug/pharmaceuticals associations.

    As per the said letter, manufacturers who are already holding licenses from State Licensing Authorities for such FDCs before 01.10.2012 and did not apply to DCGI were required to submit their applications. The date for filing such applications expired on 22.11.2019.

    "In view of above, without prejudice to the legal validity of such product licenses, all the concerned manufacturers/stakeholders are requested to submit their application along with requisite fees as specified in the Sixth Schedule of the New Drugs and Clinical Trial Rules, 2019 by 30.05.2020, " the notice added.

    For more details click on the link below:-

    https://business.medicaldialogues.in/pdf_upload/pdf_upload-124283.pdf
    dcgicdscofdc drugsfixed dose combinationKokate Committeecategory d fdc

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok